Overview of Novomit (Prochlorperazine)
Quick Facts
| Property | Description |
|---|---|
| Active Ingredient | Prochlorperazine |
| Pharmacological Class | Phenothiazine Antipsychotic / Antiemetic |
| Common Forms | Tablet, Suppository, Injection Solution |
| General Purpose | Relieves severe nausea, vomiting, and vertigo |
| Origin | Synthetic (Phenothiazine derivative) |
Defining Prochlorperazine: Classification and Origin
Prochlorperazine, the active ingredient and INN (International Nonproprietary Name) for medicines such as Novomit, is a potent, synthetic compound chemically classified as a phenothiazine derivative. It is formally recognized as a first-generation antipsychotic but is primarily utilized as a highly effective antiemetic (anti-sickness medicine). It exerts a targeted action on the central nervous system, where it influences dopamine receptors. This dual role capacity means the drug possesses the necessary potency to manage severe symptoms that may be resistant to less powerful treatments. The medicine is typically formulated as a salt, such as prochlorperazine maleate or prochlorperazine edisylate, depending on the intended dosage form.
Forms of Prochlorperazine and General Purpose
Prochlorperazine is supplied in several high-level dosage forms, including the conventional oral tablet, a suppository for rectal administration, and a solution for injection administered parenterally. This diverse availability is a key differentiating feature, ensuring treatment can be delivered even during acute episodes of severe illness. The medicine’s general purpose is to provide rapid and powerful relief from debilitating nausea and vomiting, as well as associated balance issues like vertigo (dizziness or spinning). The availability of non-oral forms is crucial when a patient is actively vomiting, preventing them from swallowing a tablet, thereby ensuring the continuation of care.
The Mechanism of a Propylpiperazine Derivative
This medicine is chemically a propylpiperazine derivative of phenothiazine, a structure that grants it a high degree of targeted pharmacological activity. It works primarily by acting as a Dopamine D2 receptor antagonist, which means it effectively blocks key chemical signals from stimulating the chemoreceptor trigger zone (CTZ)—the brain’s main vomiting control center. This specific mechanism provides the ability to control severe, centrally-driven symptoms. Its action against dopamine and other neurotransmitter receptors also allows it to moderate signals related to inner ear function, further contributing to relief from dizziness and vertigo.
Regulatory References
_EN.png)
